Paquet Éric R, Hovington Hélène, Brisson Hervé, Lacombe Cédric, Larue Hélène, Têtu Bernard, Lacombe Louis, Fradet Yves, Lebel Michel
Centre de Recherche sur le Cancer de l'Université Laval, 9 McMahon Street, Québec City, Québec, Canada.
Biomark Med. 2015;9(3):187-97. doi: 10.2217/bmm.14.115.
We determined whether the Y-box binding protein-1 (YB-1) and its binding partner, the X-linked ribosomal protein S4 (RPS4X), are associated with clinical outcome in bladder cancer.
MATERIALS & METHODS: A population of 167 patients with muscle-invasive bladder tumor without evidence of metastasis at time of cystectomy was analyzed retrospectively. YB-1 and RPS4X expressions were evaluated immunohistochemically in tumors and analyzed for association with clinical variables and survival.
Kaplan-Meier and multivariate Cox regression analyses indicated that low expression of RPS4X was associated with a higher risk of death or disease recurrence. In contrast, YB-1 was not significantly associated with either recurrence-free or overall survival.
Low RPS4X expression is associated with poor disease-specific and recurrence-free survival in bladder cancer.
我们确定了Y盒结合蛋白-1（YB-1）及其结合伴侣X连锁核糖体蛋白S4（RPS4X）是否与膀胱癌的临床预后相关。
回顾性分析了167例接受膀胱切除术时无转移证据的肌层浸润性膀胱肿瘤患者。采用免疫组织化学方法评估肿瘤中YB-1和RPS4X的表达，并分析其与临床变量和生存率的相关性。
Kaplan-Meier和多变量Cox回归分析表明，RPS4X低表达与更高的死亡或疾病复发风险相关。相比之下，YB-1与无复发生存率或总生存率均无显著相关性。
RPS4X低表达与膀胱癌患者较差的疾病特异性生存率和无复发生存率相关。
